|
|
G2 |
|
Vaxjo ID |
314 |
|
Vaccine Adjuvant Name |
G2 |
|
Adjuvant VO ID |
VO_0005270
|
|
Description |
G2 adjuvant leads to upregulation of gene expression and increases the expression of NKG2D receptor on the surface of NK cells after incubation. It increases NK cell cytotoxicity and may play an important role in killing tumor cells, preventing tumor growth and metastasis. It is classified as an immunologic adjuvant. |
|
Stage of Development |
Research |
|
Host Species for Testing |
3 |
|
Components |
G2 adjuvant leads to upregulation of gene expression and increases the expression of NKG2D receptor on the surface of NK cells after incubation |
|
Function |
The findings of this study demonstrated that G2 adjuvant can increase NK cell cytotoxicity. It may play an important role in killing tumor cells, preventing tumor growth and metastasis. |
| Related Vaccine(s) |
|
| References |
Khodadadi et al., 2016: Khodadadi A, Abdoli Z, Boroujerdnia MG, Assarehzadegan MA, Ghasemi M, Hazrati SM, Gerdabi ND. The Effect of G2 Adjuvant on Gene Expression and Delivery of NKG2D Receptor on NK Cells in Peripheral Blood. Cancer biotherapy & radiopharmaceuticals. 2016; 31(4); 119-124. [PubMed: 27183434].
|
|
